Overview of Prostaglandin E2 (PGE2)-Targeting Radiolabelled Imaging Probes from Preclinical Perspective: Lessons Learned and Road Ahead

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Apr 28

PMID 37108106

Authors

Zita Kepes

Noemi Denes

Istvan Kertesz

Istvan Hajdu

Gyorgy Trencsenyi

Affiliations

Soon will be listed here.

Abstract

As malignancies still represent one of the major health concerns worldwide, early tumor identification is among the priorities of today's science. Given the strong association between cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2), PGE2 receptors (EPs), and carcinogenesis, target-specific molecules directed towards the components of the COX2/PGE2/EP axis seem to be promising imaging probes in the diagnostics of PGE2pos. neoplasms and in the design of anti-cancer drugs. Featured with outstanding inclusion forming capability, β-cyclodextrins (CDs) including randomly methylated β-CD (RAMEB) were reported to complex with PGE2. Therefore, radiolabelled β-CDs could be valuable vectors in the molecular imaging of PGE2-related tumorigenesis. In vivo preclinical small animal model systems applying positron emission tomography (PET) ensure a well-suited scenario for the assessment of PGE2-affine labelled CD derivatives. Previous translational studies dealt with the evaluation of the tumor-homing capability of Gallium-68 (Ga) and Bismuth-205/206 (Bi)-appended β-CD compounds conjugated with chelator NODAGA or DOTAGA: [Ga]Ga-NODAGA-2-hydroxypropyl-β-cyclodextrin/HPBCD, [Ga]Ga-NODAGA-RAMEB, [Ga]Ga-DOTAGA-RAMEB, and [Bi]Bi-DOTAGA-RAMEB in experimental tumors with different PGE2 expression. These imaging probes project the establishment of tailor-made PET diagnostics of PGE2pos. malignancies. In the present review, we provide a detailed overview of the in vivo investigations of radiolabelled PGE2-directed CDs, highlighting the importance of the integration of translational discoveries into routine clinical usage.

References

Brown D, Phipps R . Characterization and regulation of prostaglandin E2 receptors on normal and malignant murine B lymphocytes. Cell Immunol. 1995; 161(1):79-87. DOI: 10.1006/cimm.1995.1011. View

Frijlink H, Visser J, Hefting N, Oosting R, Meijer D, Lerk C . The pharmacokinetics of beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin in the rat. Pharm Res. 1990; 7(12):1248-52. DOI: 10.1023/a:1015929720063. View

Wang D, DuBois R . Prostaglandins and cancer. Gut. 2005; 55(1):115-22. PMC: 1856377. DOI: 10.1136/gut.2004.047100. View

Gould S, Scott R . 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol. 2005; 43(10):1451-9. DOI: 10.1016/j.fct.2005.03.007. View

Kochel T, Fulton A . Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer. Prostaglandins Other Lipid Mediat. 2014; 116-117:99-103. PMC: 4385402. DOI: 10.1016/j.prostaglandins.2014.11.003. View

Tong D, Liu Q, Wang L, Xie Q, Pang J, Huang Y . The roles of the COX2/PGE2/EP axis in therapeutic resistance. Cancer Metastasis Rev. 2018; 37(2-3):355-368. DOI: 10.1007/s10555-018-9752-y. View

Brown J, DuBois R . COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol. 2005; 23(12):2840-55. DOI: 10.1200/JCO.2005.09.051. View

Lattuada L, Barge A, Cravotto G, Giovenzana G, Tei L . The synthesis and application of polyamino polycarboxylic bifunctional chelating agents. Chem Soc Rev. 2011; 40(5):3019-49. DOI: 10.1039/c0cs00199f. View

Downward J . Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003; 3(1):11-22. DOI: 10.1038/nrc969. View

10.

Gee J, Montoya R, Khaled H, Sabichi A, Grossman H . Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder. Urol Oncol. 2003; 21(4):266-70. DOI: 10.1016/s1078-1439(02)00271-5. View

11.

Fedyk E, Brown D, Phipps R . PGE2 regulation of B lymphocytes and T helper 1 and T helper 2 cells: induction of inflammatory versus allergic responses. Adv Exp Med Biol. 1997; 407:237-42. DOI: 10.1007/978-1-4899-1813-0_35. View

12.

Yao M, Zhou W, Sangha S, Albert A, Chang A, Liu T . Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res. 2005; 11(4):1618-28. DOI: 10.1158/1078-0432.CCR-04-1696. View

13.

Zhang Z, Sheng H, Shao J, Beauchamp R, DuBois R . Posttranscriptional regulation of cyclooxygenase-2 in rat intestinal epithelial cells. Neoplasia. 2001; 2(6):523-30. PMC: 1508084. DOI: 10.1038/sj.neo.7900117. View

14.

Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, De Haas M . The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003; 100(16):9244-9. PMC: 170903. DOI: 10.1073/pnas.1033060100. View

15.

Mate G, Kertesz I, Enyedi K, Mezo G, Angyal J, Vasas N . In vivo imaging of Aminopeptidase N (CD13) receptors in experimental renal tumors using the novel radiotracer (68)Ga-NOTA-c(NGR). Eur J Pharm Sci. 2015; 69:61-71. DOI: 10.1016/j.ejps.2015.01.002. View

16.

Yip-Schneider M, Barnard D, Billings S, Cheng L, Heilman D, Lin A . Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis. 2000; 21(2):139-46. DOI: 10.1093/carcin/21.2.139. View

17.

Borgstrom P, Oh P, Czarny M, Racine B, Schnitzer J . Co-implanting orthotopic tissue creates stroma microenvironment enhancing growth and angiogenesis of multiple tumors. F1000Res. 2014; 2:129. PMC: 3976108. DOI: 10.12688/f1000research.2-129.v2. View

18.

Kochel T, Reader J, Ma X, Kundu N, Fulton A . Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer. Oncotarget. 2016; 8(4):6540-6554. PMC: 5351651. DOI: 10.18632/oncotarget.14145. View

19.

Phelps M . Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci U S A. 2000; 97(16):9226-33. PMC: 16850. DOI: 10.1073/pnas.97.16.9226. View

20.

Szabo J, Csige K, Kalman-Szabo I, Arato V, Opposits G, Joszai I . In vivo assessment of tumor targeting potential of Ga-labelled randomly methylated beta-cyclodextrin (RAMEB) and 2-hydroxypropyl-β-cyclodextrin (HPβCD) using positron emission tomography. Int J Pharm. 2022; 630:122462. DOI: 10.1016/j.ijpharm.2022.122462. View